Further animal model studies have shown that PIK3CA mutations exacerbate lesions in CCM and MAP3K3 mutant mouse models, and the use of the mTOR inhibitor rapamycin can inhibit CCM formation.83 This evidence concerns the gene MAP3K3 and cerebral cavernous malformation.